VIA
BIO icon

Vident Investment Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vident Investment Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,537
Closed -$736K – 1194
2023
Q1 		$736K Buy
1,537
+391
+34% +$183K 0.02% 625
2022
Q4 		$482K Buy
1,146
+196
+21% +$79.1K 0.02% 733
2022
Q3 		$362K Buy
950
+324
+52% +$162K 0.01% 853
2022
Q2 		$301K Sell
626
-1,662
-73% -$866K 0.01% 1011
2022
Q1 		$1.29M Buy
2,288
+327
+17% +$197K 0.03% 606
2021
Q4 		$1.48M Buy
1,961
+789
+67% +$590K 0.04% 577
2021
Q3 		$874K Buy
1,172
+75
+7% +$56.2K 0.03% 725
2021
Q2 		$708K Sell
1,097
-67
-6% -$40.8K 0.02% 748
2021
Q1 		$665K Buy
1,164
+59
+5% +$34.9K 0.02% 712
2020
Q4 		$645K Buy
1,105
+12
+1% +$6.83K 0.03% 648
2020
Q3 		$563K Sell
1,093
-83
-7% -$42K 0.03% 638
2020
Q2 		$531K Buy
+1,176
New +$519K 0.03% 628
2015
Q4 		– Sell
-6,378
Closed -$857K – 427
2015
Q3 		$857K Buy
+6,378
New +$918K 0.12% 242

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vident Investment Advisory's BIO Position: Q2 2023 in Review

Vident Investment Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 1,537 shares — an estimated $736K sold.

Vident Investment Advisory first reported a position in BIO in Q3 2015 and held it in 13 quarters. The position peaked at $1.48M in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Vident Investment Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 1,537 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $736K.
  • Vident Investment Advisory first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and held it in 13 quarters.
  • Vident Investment Advisory's Bio-Rad Laboratories Class A position peaked at $1.48M in Q4 2021.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.